Search

649 Result(s)
Sort by

BTD for GlyT1 in Schizophrenia

BTD for GlyT1 in Schizophrenia

Boehringer Ingelheim’s Investigational Treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation
Collaboration to fight NCDs

Collaboration to fight NCDs

70 percent of global deaths are attributable to NCDs and severely impacting on people in low- and middle-income countries. Help is desperately needed.
Oncology

Oncology

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
Innovating for our business

Innovating for our business

We drive innovation across our complex business landscape at Boehringer Ingelheim. Technology is an integral part of our core business processes and we focus on advanced technologies.
Immunology

Immunology

Human Pharma Clinical Pipeline Immunology therapeutic area
Combating complex diseases with data

Combating complex diseases with data

How does big data create disrupting insights for our company? Read about potential use cases and promoting a data mindset
Digital solutions save lives

Digital solutions save lives

Michael Schmelmer explains how digital solutions shape the future of Boehringer Ingelheim and the entire healthcare industry.
Jardiance®

Jardiance®

Treatment of adults with type 2 diabetes mellitus as an adjunct to diet and exercise.
BIVF funding more than doubled to 250 M€

BIVF funding more than doubled to 250 M€

Boehringer Ingelheim increases funding for its corporate venture fund, the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million
collaboration-Yale

collaboration-Yale

Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World
Eyes on Retina. The Podcast

Eyes on Retina. The Podcast

Hear from experts and people living with retinal diseases such as wet age-related macular degeneration (AMD), stargardt disease and diabetic retinopathy.
Conversations Beyond Type 2 Diabetes

Conversations Beyond Type 2 Diabetes

Anne and Franc, who are living with T2D, explore what it means to live with their condition and its associated comorbidities.
Our Partners Harvard

Our Partners Harvard

Brock Reeve, Executive Director of the Harvard Stem Cell Institute, talks about the importance of working together to tackle the challenge of fibrosis.
Our Partners Bioharmony

Our Partners Bioharmony

Chandra Ghose, Founder and CEO of Bioharmony Therapeutics, talks about the urgent need for developing new antimicrobials and the benefits of partnering with Boehringer Ingelheim.
Respiratory

Respiratory

Human Pharma Clinical Pipeline Respiratory therapeutic area